-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Acumen Pharmaceuticals (NASDAQ:ABOS) Versus Immunovant (NASDAQ:IMVT) Critical Review
Acumen Pharmaceuticals (NASDAQ:ABOS) Versus Immunovant (NASDAQ:IMVT) Critical Review
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Immunovant (NASDAQ:IMVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Risk & Volatility
Acumen Pharmaceuticals has a beta of -1.92, meaning that its stock price is 292% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Get Acumen Pharmaceuticals alerts:Profitability
This table compares Acumen Pharmaceuticals and Immunovant's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Immunovant | N/A | -39.15% | -36.36% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Acumen Pharmaceuticals and Immunovant, as provided by MarketBeat.com.| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Immunovant | 0 | 1 | 4 | 0 | 2.80 |
Acumen Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 200.97%. Immunovant has a consensus target price of $16.86, suggesting a potential downside of 8.73%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Immunovant.
Earnings and Valuation
This table compares Acumen Pharmaceuticals and Immunovant's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 165.11 | -$100.61 million | N/A | N/A |
| Immunovant | N/A | N/A | -$156.73 million | ($1.53) | -12.07 |
Acumen Pharmaceuticals has higher revenue and earnings than Immunovant.
Insider and Institutional Ownership
67.9% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of Immunovant shares are held by institutional investors. 4.7% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Acumen Pharmaceuticals beats Immunovant on 8 of the 10 factors compared between the two stocks.
About Acumen Pharmaceuticals
(Get Rating)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
About Immunovant
(Get Rating)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Immunovant (NASDAQ:IMVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Acumen PharmPharmticals(纳斯达克：ABOS-GET Rating)和免疫药业(纳斯达克：IMVT-GET Rating)都是医药公司，但哪只股票更好？我们将根据两家公司的机构持股、股息、收益、风险、分析师建议、盈利能力和估值等方面的实力进行比较。
Risk & Volatility
风险与波动性
Acumen Pharmaceuticals has a beta of -1.92, meaning that its stock price is 292% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
Acumen PharmPharmticals的贝塔系数为-1.92，这意味着其股价的波动性比标准普尔500指数低292%。相比之下，Invovant的贝塔系数为1.03，这意味着其股价的波动性比标准普尔500指数高出3%。
Profitability
盈利能力
This table compares Acumen Pharmaceuticals and Immunovant's net margins, return on equity and return on assets.
此表比较了Acumen制药公司和免疫药物公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Acumen Pharmaceuticals | N/A | -18.16% | -17.72% |
| Immunovant | N/A | -39.15% | -36.36% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Acumen制药公司 | 不适用 | -18.16% | -17.72% |
| 免疫抗体 | 不适用 | -39.15% | -36.36% |
Analyst Ratings
分析师评级
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acumen Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
| Immunovant | 0 | 1 | 4 | 0 | 2.80 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Acumen制药公司 | 0 | 0 | 3 | 0 | 3.00 |
| 免疫抗体 | 0 | 1 | 4 | 0 | 2.80 |
Acumen Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 200.97%. Immunovant has a consensus target price of $16.86, suggesting a potential downside of 8.73%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Immunovant.
Acumen PharmPharmticals目前的共识目标价为17.67美元，暗示潜在上涨200.97%。免疫药物的普遍目标价为16.86美元，这意味着潜在的下跌8.73%。考虑到Acumen PharmPharmticals更强的共识评级和更高的可能上行空间，分析师显然认为Acumen PharmPharmticals比Immunovant更有利。
Earnings and Valuation
收益和估值
This table compares Acumen Pharmaceuticals and Immunovant's gross revenue, earnings per share and valuation.
此表比较了Acumen制药公司和免疫药物公司的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acumen Pharmaceuticals | $1.44 million | 165.11 | -$100.61 million | N/A | N/A |
| Immunovant | N/A | N/A | -$156.73 million | ($1.53) | -12.07 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Acumen制药公司 | 144万美元 | 165.11 | -1.0061亿美元 | 不适用 | 不适用 |
| 免疫抗体 | 不适用 | 不适用 | -1.5673亿美元 | ($1.53) | -12.07 |
Acumen Pharmaceuticals has higher revenue and earnings than Immunovant.
Acumen制药公司的收入和收益比免疫药物更高。
Insider and Institutional Ownership
内部人与机构持股
67.9% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of Immunovant shares are held by institutional investors. 4.7% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Acumen PharmPharmticals 67.9%的股份由机构投资者持有。相比之下，免疫公司32.8%的股份由机构投资者持有。Acumen PharmPharmticals 4.7%的股份由内部人士持有。相比之下，免疫公司3.0%的股份由内部人士持有。强大的机构持股表明，对冲基金、大型基金管理公司和捐赠基金相信，一只股票的长期表现将好于大盘。
Summary
摘要
Acumen Pharmaceuticals beats Immunovant on 8 of the 10 factors compared between the two stocks.
Acumen PharmPharmticals在两只股票的10个因素中有8个超过了免疫药物。
About Acumen Pharmaceuticals
关于Acumen制药公司
(Get Rating)
(获取评级)
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen制药公司是一家临床阶段的生物制药公司，发现和开发治疗阿尔茨海默病的疗法。该公司专注于开发一种靶向免疫治疗候选药物ACU193，这是一种人源化单抗，正处于I期临床阶段，用于靶向可溶性淀粉样β寡聚体。Acumen制药公司成立于1996年，总部设在弗吉尼亚州夏洛茨维尔。
About Immunovant
关于免疫调节剂
(Get Rating)
(获取评级)
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
免疫公司是一家临床阶段的生物制药公司，开发用于治疗自身免疫性疾病的单抗。它开发了一种新型的全人类单抗Batotopab，它选择性地结合和抑制新生儿片段结晶受体，该受体正处于治疗重症肌无力和甲状腺眼病的IIa期临床试验，以及治疗温热自身免疫性溶血性贫血的II期临床试验的完成。该公司成立于2018年，总部设在纽约。免疫公司是罗万特科学有限公司的子公司。
Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acumen PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acumen制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧